Revolution Medicines shows severe financial deterioration with net losses nearly doubling to $1.1B while cash reserves declined 29% and total liabilities increased 147%.
The company is burning through cash at an accelerated rate with operating cash outflows increasing 61% to nearly $900M annually, while R&D expenses surged 67% to nearly $1B. The dramatic increase in liabilities combined with declining cash position and doubled losses raises serious concerns about the company's financial runway and ability to fund operations through drug development timelines.
Revolution Medicines experienced severe financial deterioration across all key metrics, with net losses nearly doubling from $600M to $1.1B while cash reserves declined $159M to $384M. The company dramatically increased R&D spending by 67% to $987M, driving operating losses up 72% to $1.2B, while total liabilities surged 147% to $723M and stockholders' equity fell 28% to $1.6B. This combination of accelerating losses, declining cash, and rising liabilities signals a company burning through capital at an unsustainable rate to fund its drug development pipeline.
Liabilities grew 146.7% — significant increase in debt or obligations, assess impact on financial flexibility.
Net income declined 88.5% — review whether driven by operations, interest costs, or non-recurring items.
Current liabilities surged 77.2% — significant near-term obligations; verify ability to meet short-term debt.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
R&D investment increased 66.7% — signals commitment to future product development, though near-term margin impact.
Operating cash flow fell 61% — earnings quality concerns; investigate working capital changes and non-cash items.
Capital expenditure jumped 55.1% — major investment cycle underway; assess returns on deployment.
Cash decreased 29.3% — monitor burn rate and upcoming capital needs.
Equity decreased 28% — buybacks or losses reducing book value, monitor solvency ratios.
Current assets declined 10.9% — monitor working capital adequacy and short-term liquidity.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →